This NINDS/NIA sponsored workshop brings together leading experts and researchers from around the world to discuss the latest advancements and challenges in the field of anti-beta amyloid passive immunotherapy. 

Two anti-beta amyloid antibodies, aducanumab and lecanemab, have received accelerated approval by the FDA for the treatment of mild to moderate Alzheimer’s disease, and Phase 3 trials for several additional antibodies are currently underway. 

During the clinical trials for this anti-beta amyloid immunotherapy, however, MRI abnormalities have been reported as an adverse treatment effect, termed “amyloid-related imaging abnormalities” (ARIA). Some patients have experienced severe side effects, including leaky blood-brain barrier, edema, and brain hemorrhage. Therefore, it is critical to better understand the benefits and risks associated with this therapy and strategies to improve efficacy and safety. 

Goals of this workshop are to identify scientific gaps and opportunities, discuss potential animal models, learn how to identify patients at risk for serious adverse events, understand the role for comorbidities and their treatments, and identify potential biomarkers or targets to protect patients at risk.